Results showed that Orlistat treatment significantly reduced EGFR palmitoylation (Fig 5D), suggesting a functional relationship between FASN and EGFR palmitoylation in TKI‐resistant EGFR mutant NSCLC cells. The gene discussed is FASN; the disease is non-small cell lung carcinoma.